相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Effectiveness and safety of empagliflozin in routine care patients: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study
Elisabetta Patorno et al.
DIABETES OBESITY & METABOLISM (2022)
The effect of empagliflozin on the total burden of cardiovascular and hospitalization events in the Asian and non-Asian populations of the EMPA-REG OUTCOME trial of patients with type 2 diabetes and cardiovascular disease
Kohei Kaku et al.
DIABETES OBESITY & METABOLISM (2022)
Healthcare resource utilization in patients treated with empagliflozin in East Asia
Wayne H-H Sheu et al.
JOURNAL OF DIABETES INVESTIGATION (2022)
Characterization and implications of the initial estimated glomerular filtration rate 'dip' upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial
Bettina J. Kraus et al.
KIDNEY INTERNATIONAL (2021)
Rationale and design of the EMPA-ELDERLY trial: a randomised, double-blind, placebo-controlled, 52-week clinical trial of the efficacy and safety of the sodium-glucose cotransporter-2 inhibitor empagliflozin in elderly Japanese patients with type 2 diabetes
Daisuke Yabe et al.
BMJ OPEN (2021)
Cardiovascular and renal effectiveness of empagliflozin in routine care in East Asia: Results from the EMPRISE East Asia study
Yutaka Seino et al.
ENDOCRINOLOGY DIABETES & METABOLISM (2021)
Safety and effectiveness of empagliflozin in Japanese patients with type 2 diabetes: interim analysis from a post-marketing surveillance study
Kohei Kaku et al.
EXPERT OPINION ON DRUG SAFETY (2020)
Recommendations on the Proper Use of SGLT2 Inhibitors
Norio Abiru et al.
JOURNAL OF DIABETES INVESTIGATION (2020)
Efficacy and safety of empagliflozin as add-on to insulin in Japanese patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial
Hirohito Sone et al.
DIABETES OBESITY & METABOLISM (2020)
Pooled Safety and Tolerability Analysis of Empagliflozin in Patients with Type 2 Diabetes Mellitus
Ona Kinduryte Schorling et al.
ADVANCES IN THERAPY (2020)
Japanese Clinical Practice Guideline for Diabetes 2019
Eiichi Araki et al.
JOURNAL OF DIABETES INVESTIGATION (2020)
Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial
Darren K McGuire et al.
Lancet Diabetes & Endocrinology (2020)
Sodium-glucose cotransporter 2 inhibitor-induced changes in body composition and simultaneous changes in metabolic profile: 52-week prospective LIGHT (Luseogliflozin: the Components of Weight Loss in Japanese Patients with Type 2 Diabetes Mellitus) Study
Takashi Sasaki et al.
JOURNAL OF DIABETES INVESTIGATION (2019)
Safety and Efficacy of Empagliflozin as Add-On Therapy to GLP-1 Receptor Agonist (Liraglutide) in Japanese Patients with Type 2 Diabetes Mellitus: A Randomised, Double-Blind, Parallel-Group Phase 4 Study
Yasuo Terauchi et al.
DIABETES THERAPY (2019)
Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care A First Analysis From the EMPRISE Study
Elisabetta Patorno et al.
CIRCULATION (2019)
Safety and tolerability of empagliflozin in East Asian patients with type 2 diabetes: Pooled analysis of phase I-III clinical trials
Daisuke Yabe et al.
JOURNAL OF DIABETES INVESTIGATION (2019)
Effect of Empagliflozin on Free Fatty Acids and Ketone Bodies in Japanese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial
Rimei Nishimura et al.
ADVANCES IN THERAPY (2019)
Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME® trial
Pedro Monteiro et al.
AGE AND AGEING (2019)
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
S. D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA-REG OUTCOMEA® trial
Takashi Kadowaki et al.
JOURNAL OF DIABETES INVESTIGATION (2019)
A Review of the Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors on Lean Body Mass in Humans
Jack Alistair Sargeant et al.
ENDOCRINOLOGY AND METABOLISM (2019)
Empagliflozin as add-on to linagliptin in a fixed-dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a 52-week, randomized, placebo-controlled trial
Ryuzo Kawamori et al.
DIABETES OBESITY & METABOLISM (2018)
Incidence of diabetic foot ulcer in Japanese patients with type 2 diabetes mellitus: The Fukuoka diabetes registry
Masanori Iwase et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2018)
Empagliflozin: A Review in Type 2 Diabetes
James E. Frampton
DRUGS (2018)
Empagliflozin Induces Transient Diuresis Without Changing Long-Term Overall Fluid Balance in Japanese Patients With Type 2 Diabetes
Atsutaka Yasui et al.
DIABETES THERAPY (2018)
Empagliflozin Induces Transient Diuresis Without Changing Long-Term Overall Fluid Balance in Japanese Patients With Type 2 Diabetes
Atsutaka Yasui et al.
DIABETES THERAPY (2018)
Empagliflozin on top of metformin treatment improves arterial function in patients with type 1 diabetes mellitus
Mojca Lunder et al.
CARDIOVASCULAR DIABETOLOGY (2018)
Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Melanie J. Davies et al.
DIABETES CARE (2018)
Empagliflozin and Assessment of Lower-Limb Amputations in the EMPA-REG OUTCOME Trial
Silvio E. Inzucchi et al.
DIABETES CARE (2018)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk
Bernard Zinman et al.
STROKE (2017)
Effects of the Selective Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin on Vascular Function and Central Hemodynamics in Patients With Type 2 Diabetes Mellitus
Kristina Striepe et al.
CIRCULATION (2017)
Efficacy and safety of empagliflozin in Japanese patients with type 2 diabetes mellitus: A sub-analysis by body mass index and age of pooled data from three clinical trials
Teruo Shiba et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2017)
Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)
Mikhail Kosiborod et al.
CIRCULATION (2017)
Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes: Pooled Analysis of Phase I-III Clinical Trials
Sven Kohler et al.
ADVANCES IN THERAPY (2017)
Empagliflozin and Cardiovascular Outcomes in Asian Patients With Type 2 Diabetes and Established Cardiovascular Disease - Results From EMPA-REG OUTCOME®
Kohei Kaku et al.
CIRCULATION JOURNAL (2017)
Pharmacodynamic Effects of Single and Multiple Doses of Empagliflozin in Patients With Type 2 Diabetes
Tim Heise et al.
CLINICAL THERAPEUTICS (2016)
Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes
Ele Ferrannini et al.
DIABETES (2016)
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Christoph Wanner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Efficacy and Safety of Empagliflozin Monotherapy for 52 Weeks in Japanese Patients with Type 2 Diabetes: A Randomized, Double-Blind, Parallel-Group Study
Takashi Kadowaki et al.
ADVANCES IN THERAPY (2015)
Probing SGLT2 as a therapeutic target for diabetes: Basic physiology and consequences
Linda A. Gallo et al.
DIABETES & VASCULAR DISEASE RESEARCH (2015)
Long-term treatment with empagliflozin as add-on to oral antidiabetes therapy in Japanese patients with type 2 diabetes mellitus
E. Araki et al.
DIABETES OBESITY & METABOLISM (2015)
Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes
R. Chilton et al.
DIABETES OBESITY & METABOLISM (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus
Muhammad A. Abdul-Ghani et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2015)
The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus
David Z. I. Cherney et al.
CARDIOVASCULAR DIABETOLOGY (2014)
Type 2 diabetes in East Asians: similarities and differences with populations in Europe and the United States
Ronald C. W. Ma et al.
YEAR IN DIABETES AND OBESITY (2013)
Evaluation of Factors Influencing the Natural History of Nocturia in Elderly Subjects: Results of the Fujiwara-kyo Study
Akihide Hirayama et al.
JOURNAL OF UROLOGY (2013)
Metabolic Syndrome Is a Risk Factor for Acute Cerebral Infarction in a Younger Elderly Kurashiki Population
Yasuyuki Ohta et al.
JOURNAL OF STROKE & CEREBROVASCULAR DISEASES (2012)
Revised Equations for Estimated GFR From Serum Creatinine in Japan
Seiichi Matsuo et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2009)
Prevalence of chronic kidney disease in the Japanese general population
Enyu Imai et al.
CLINICAL AND EXPERIMENTAL NEPHROLOGY (2009)
Incidence and risk factors for subtypes of cerebral infarction in a general population - The Hisayama study
Y Tanizaki et al.
STROKE (2000)
分享论文
